|1.||Qiu, Jun: 2 articles (12/2006 - 06/2005)|
|2.||Jiang, Shao-Jun: 1 article (12/2006)|
|3.||Shen, Jian-Ping: 1 article (12/2006)|
|4.||Yin, Hong-Lin: 1 article (12/2006)|
|5.||Yin, Xiao-Xing: 1 article (12/2006)|
|6.||Yu, Jun-Xian: 1 article (12/2006)|
|7.||Zheng, Xiao-gang: 1 article (06/2005)|
|8.||Li, Li-min: 1 article (06/2005)|
|9.||Zhang, Yin-di: 1 article (06/2005)|
|10.||Yin, Xiao-xing: 1 article (06/2005)|
01/01/1989 - "A double-masked placebo-controlled clinical trial with hard data evaluation by image analysis of Scheimpflug photographs taken at baseline and 6, 12 and 18 months after starting treatment was performed to assess the efficacy of bendazac lysine in four different types of senile cataract. "
04/01/1990 - "Results from a very small number of preliminary studies using objective photographic and densitometric methods have suggested that oral bendazac lysine, usually at a dosage of 500 mg 3 times daily, can stabilise the progression of lens opacification in patients with cataract. "
10/01/1990 - "In connection with the clinical trial of an anti-cataract drug (Bendazac lysine) a number of examination methods were used to assess the progress of the cataract: slitlamp examination, visual acuity determination, and the measurement of the contrast sensitivity, light scatter in the eye and the autofluorescence and transmission of the lens. "
04/01/1990 - "Bendazac lysine is one of a number of agents which have been introduced for the management of cataract. "
01/01/1990 - "The results show that bendazac-lysine may delay the formation of lens opacities."
|2.||Peripheral Nervous System Diseases (PNS Diseases)
12/01/2006 - "4. Bendazac lysine exerts its protective effects against the progression of diabetic peripheral neuropathy in STZ-diabetic rats through multiple mechanisms and is a potential drug for the prevention of deterioration in DPN."
12/01/2006 - "Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats."
12/01/2006 - "The aim of the present study was to investigate the effects of bendazac lysine (BDL), an anticataract drug, on experimental diabetic peripheral neuropathy (DPN) in rats. "
|3.||Diabetic Nephropathies (Diabetic Nephropathy)
|4.||Renal Insufficiency (Renal Failure)
01/01/1987 - "Overall it can be assumed that the pharmacological effect of the drug will not be enhanced in renal failure and that the dosage regimen of bendazac-lysine in such patients need not be modified."
01/01/1987 - "Pharmacokinetics of bendazac-lysine and 5-hydroxybendazac in patients with renal insufficiency."
01/01/1987 - "The pharmacokinetics of bendazac and its major metabolite, 5-hydroxybendazac, have been investigated in 15 patients with moderate to severe renal insufficiency and renal failure following a single oral dose of 500 mg bendazac-lysine. "
|3.||Polymethyl Methacrylate (Sol)
|5.||bendazolic acid (bendazac)
|9.||Glutathione (Reduced Glutathione)